Pharvaris N.V.(PHVS) - 2023 Q4 - Annual Report

Recent Business Updates and Highlights Development Pipeline Exhibit 99.1 Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Zug, Switzerland, April 10, 2024 – Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. "20 ...